SG11202108607QA - Crystalline forms of a jak2 inhibitor - Google Patents
Crystalline forms of a jak2 inhibitorInfo
- Publication number
- SG11202108607QA SG11202108607QA SG11202108607QA SG11202108607QA SG11202108607QA SG 11202108607Q A SG11202108607Q A SG 11202108607QA SG 11202108607Q A SG11202108607Q A SG 11202108607QA SG 11202108607Q A SG11202108607Q A SG 11202108607QA SG 11202108607Q A SG11202108607Q A SG 11202108607QA
- Authority
- SG
- Singapore
- Prior art keywords
- hhh
- crystalline form
- degrees
- crystalline
- ray powder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1902018A FR3092581A1 (fr) | 2019-02-12 | 2019-02-12 | Formes cristallines d'un inhibiteur de jak2 |
| PCT/US2020/017764 WO2020167844A1 (en) | 2019-02-12 | 2020-02-11 | Crystalline forms of a jak2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108607QA true SG11202108607QA (en) | 2021-09-29 |
Family
ID=68281482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108607QA SG11202108607QA (en) | 2019-02-12 | 2020-02-11 | Crystalline forms of a jak2 inhibitor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220332706A1 (https=) |
| EP (1) | EP3927704A4 (https=) |
| JP (2) | JP2022520083A (https=) |
| KR (1) | KR20210148110A (https=) |
| CN (1) | CN114026088A (https=) |
| AU (1) | AU2020221796A1 (https=) |
| BR (1) | BR112021015318A2 (https=) |
| EA (1) | EA202192237A1 (https=) |
| FR (1) | FR3092581A1 (https=) |
| IL (1) | IL285427A (https=) |
| MX (1) | MX2021009423A (https=) |
| SG (1) | SG11202108607QA (https=) |
| WO (1) | WO2020167844A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021005518A2 (pt) | 2018-09-25 | 2021-06-29 | Impact Biomedicines, Inc. | métodos para tratar distúrbios mieloproliferativos |
| US12559463B2 (en) * | 2019-02-12 | 2026-02-24 | Impact Biomedicines Inc. | Crystalline forms of a JAK2 inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5191391B2 (ja) * | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| AU2010363329A1 (en) * | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| TW201316989A (zh) * | 2011-07-21 | 2013-05-01 | Sanofi Sa | 用於治療真性多血症及原發性血小板過多症之組合物及方法 |
| US10040804B2 (en) * | 2016-12-21 | 2018-08-07 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
-
2019
- 2019-02-12 FR FR1902018A patent/FR3092581A1/fr active Pending
-
2020
- 2020-02-11 JP JP2021547092A patent/JP2022520083A/ja active Pending
- 2020-02-11 CN CN202080027762.4A patent/CN114026088A/zh active Pending
- 2020-02-11 MX MX2021009423A patent/MX2021009423A/es unknown
- 2020-02-11 KR KR1020217029156A patent/KR20210148110A/ko not_active Ceased
- 2020-02-11 SG SG11202108607QA patent/SG11202108607QA/en unknown
- 2020-02-11 WO PCT/US2020/017764 patent/WO2020167844A1/en not_active Ceased
- 2020-02-11 AU AU2020221796A patent/AU2020221796A1/en not_active Abandoned
- 2020-02-11 EA EA202192237A patent/EA202192237A1/ru unknown
- 2020-02-11 BR BR112021015318-7A patent/BR112021015318A2/pt unknown
- 2020-02-11 EP EP20756422.0A patent/EP3927704A4/en active Pending
- 2020-02-11 US US17/430,148 patent/US20220332706A1/en not_active Abandoned
-
2021
- 2021-08-06 IL IL285427A patent/IL285427A/en unknown
-
2024
- 2024-12-05 JP JP2024212168A patent/JP2025032217A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114026088A (zh) | 2022-02-08 |
| JP2022520083A (ja) | 2022-03-28 |
| BR112021015318A2 (pt) | 2021-10-05 |
| WO2020167844A1 (en) | 2020-08-20 |
| JP2025032217A (ja) | 2025-03-11 |
| FR3092581A1 (fr) | 2020-08-14 |
| MX2021009423A (es) | 2021-11-17 |
| AU2020221796A1 (en) | 2021-08-12 |
| IL285427A (en) | 2021-09-30 |
| KR20210148110A (ko) | 2021-12-07 |
| EP3927704A4 (en) | 2022-12-28 |
| US20220332706A1 (en) | 2022-10-20 |
| EP3927704A1 (en) | 2021-12-29 |
| EA202192237A1 (ru) | 2021-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10023577B2 (en) | Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof | |
| JP2025032217A (ja) | Ｊａｋ２阻害剤の結晶形態 | |
| CN113840604B (zh) | Jak2抑制剂的结晶形式 | |
| US10150770B2 (en) | Crystal form of bisulfate of JAK inhibitor and preparation method therefor | |
| US11053214B2 (en) | Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists | |
| WO2020244348A1 (zh) | 呋喃并咪唑并吡啶类化合物的合成方法、呋喃并咪唑并吡啶类化合物的晶型及其盐的晶型 | |
| JP2025505655A (ja) | １－（（ｓ）－４－（（ｒ）－７－（６－アミノ－４－メチル－３－（トリフルオロメチル）ピリジン－２－イル）－６－クロロ－８－フルオロ－２－（（（ｓ）－１－メチルピロリジン－２－イル）メトキシ）キナゾリン－４－イル）－３－メチルピペラジン－１－イル）プロパ－２－エン－１－オンの固体形態 | |
| EP4186908B1 (en) | Jak inhibitor compound and use thereof | |
| TW202033517A (zh) | Bcl-2抑制劑的新穎鹽、相關的結晶形式、其製備方法及包含其之醫藥組合物 | |
| US20250101017A1 (en) | Salt crystal form and free base crystal form of kinase inhibitor | |
| EP4382528A1 (en) | Crystal form of ripk1 inhibitor, acid salt thereof, and crystal form of acid salt thereof | |
| US10544129B2 (en) | Crystalline forms of AP26113, and preparation method thereof | |
| JP2021527120A (ja) | 塩形態 | |
| US20230192710A1 (en) | Jak inhibitor compound and use thereof | |
| TW202506661A (zh) | 一種酪氨酸激酶抑制劑的可藥用鹽、結晶形式及其製備方法 | |
| CN120457133A (zh) | Jak1/tyk2抑制剂的多晶型物及其用途 | |
| EP3845534A1 (en) | Salt form and crystal form of novel azatricyclic compound and use thereof | |
| WO2016081538A1 (en) | Solid state forms of ceritinib and salts thereof | |
| CA2944150A1 (en) | Polymorphic forms and co-crystals of a c-met inhibitor |